Search results
Results from the WOW.Com Content Network
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. [4] The deal was closed on June 9, 2010.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The top 5 best selling pharmaceuticals 2015–2019. Sales in billion USD. [1] Rank Drug ... Astellas Pharma US: Overactive bladder: Feb-2000: 2018-Nov 68: Dexilant:
Pages for logged out editors learn more. Contributions; Talk; Astellas US LLC
Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. [3]
Pfizer is one of the top pharmaceutical companies in the United States, with a market capitalization of $150.35 billion as of December 31, 2024. It ranks fifth among U.S. pharma companies. As of 2024, the company holds the 69th position on the Fortune 500 list. [5] [6]
On March 3, 2010, Medivation's stock dropped $27.15 per share to close at $13.10, a 67% one-day decline on volume of 45 million shares. [9] In response, a security fraud class-action lawsuit was initiated by Izard Nobel LLP, [10] alleging that Medivation made false and misleading statements regarding the effectiveness of Dimebon as a treatment for Alzheimer's disease, before being revealed ...